{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'DNA); positive hepatitis C virus antibody (HCV-Ab) confirmed by positive hepatitis C', 'virus RNA (HVC RNA).', 'E 25. Liver injury related criteria:', '-', 'Clinically significant/active hepatobiliary disease or', '-', 'Elevated transaminases (alanine aminotransferase [ALT] and/or aspartate', 'aminotransferase [AST]) >3 Upper Limit of Normal (ULN).', 'E 26. Abnormal lab values at Screening:', '-', 'Creatine phosphokinase (CPK) >3 ULN or', '-', 'Platelets <100 000 cells/mm\u00b3 or', '-', 'Eosinophils >1500 cells/mm\u00b3 or', 'E 27. Patients receiving live (attenuated) vaccines within 4 weeks before the baseline visit.', '7.2.4 Additional Exclusion Criteria During or at the end of Screening or Run-in phase', 'before randomization', 'E', '28. Patient and/or parent(s)/caregiver(s)/lega guardian(s) who has/have withdrawn consent', 'before enrollment/randomization (starting from signed informed consent form', '[ICF]/informed assent form [IAF]).', 'E 29. Despite screening of the patient, enrollment/randomization is stopped at the study level.', 'Property of the Sanofi Group - strictly confidential', 'Page 48', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '8', 'STUDY TREATMENTS', '8.1', 'INVESTIGATIONAL MEDICINAL PRODUCT(S)', '8.1.1 Dupilumab', 'Dupilumab for children <30 kg bw at randomization: 150 mg/mL in pre-filled syringe to deliver a', 'once q2w dose of 100 mg in a 0.67 mL subcutaneous injection.', 'Dupilumab for children >30 kg bw at randomization: 175 mg/mL in pre-filled syringe to deliver a', 'once q2w dose of 200 mg in a 1.14 mL subcutaneous injection.', '8.1.2 Placebo', 'Matching placebo in a prefilled syringe to deliver a once q2w dose of placebo in a 0.67 mL or', '1.14 mL subcutaneous injection for children with 30 or >30 kg bw at randomization,', 'respectively.', '8.1.3 Preparation of investigational product', 'Dupilumab or matching placebo in glass pre-filled syringes will be dispensed to the patients.', 'Additional information will be provided in the Pharmacy manual.', '8.1.4 Dosing schedule', 'The IMP is administered every 14+3 days q2w. The doses of investigational product must be', 'separated by >11 days to avoid overdose.', 'The IMP administrations will be performed by the Investigator or designee at scheduled study site', 'visits following clinic procedures and blood collection (see Section 1.2). Patients will be', 'monitored for a minimum of 30 minutes after each study-site administrated injection of IMP, to', 'assess any injection site reactions (eg, for any signs or symptoms of a hypersensitivity reaction).', 'For all visits scheduled only for IMP administration, parent(s)/caregiver(s)/legal guardian(s) may', 'decide to do the injection of IMP at home (ie, home administration of IMP). These', 'parent(s)/caregiver(s)/legal guardian(s) will be trained by the Investigator or designee to', 'administer IMP, by demonstration at Visit 2, Visit 3, and Visit 4 (injections performed by', 'Investigator). After parent(s)/caregiver(s)/legal guardian(s) have successfully administered IMP', 'under close supervision of the Investigator at Visit 5-Visit 8 (Weeks 6, 8, 10, and 12), the', 'Investigator may approve them to perform home administration of IMP at all further visits that do', 'not require a scheduled clinic visit (ie, , at Weeks 14,18,22,26,30,34,38,42, 46, and 50).', 'Patients should be monitored for 30 minutes after home administration of IMP. It is possible to', 'start home administration at any visit following Visit 9, provided parent(s)/caregiver(s)/legal', 'guardian(s) have been trained by the investigator or designee to administer IMP by demonstration', 'Property of the Sanofi Group - strictly confidential', 'Page 49', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'at not less than 3 visits followed by a successful IMP administration under close supervision of', 'the investigator or designee at not less than 3 visits.', 'However, if parent(s)/caregiver(s)/legal guardian(s) do not develop the comfort to inject the IMP', 'at home, or the Investigator determines that injection by parent(s)/caregiver(s)/legal guardian(s) at', 'home is not appropriate, alternative arrangements may be made: for example for qualified site', 'personnel and/or healthcare professionals (eg, visiting nurse service) to administer IMP at these', \"timepoints at the patient's home.\", 'For IMP doses not given at the study site, \"home dosing diary\\' (paper format) will be provided to', 'record information related to the injections. Such home dosing diaries will be kept as source data', \"in the patient's study file.\", 'Parent(s)/caregiver(s)/legal guardian(s) should be instructed to avoid missing any site visits (ie,', 'IMP doses) or doses of background therapy during the study. For any patient who misses a', 'site-visit (ie, IMP dose) or doses of background therapy, the parent(s)/caregiver(s)/legal', 'guardian(s) should be reminded to be diligent to avoid missed visits and doses of background', 'therapy thereafter.', 'The patient(s)/parent(s)/caregiver(s)/legal guardian(s) should continue their scheduled visits for', 'IMP treatment (with study procedures, as detailed in Section 1.2), even if more than 2 consecutive', 'doses of IMP are missed, or background medication was not taken by the patient(s) for up to', '2-4 days.', 'The SC injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel', 'and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice', 'consecutively. For each injection, the anatomic site of administration will be recorded in the', 'electronic-case report form (e-CRF) or, as applicable, the home dosing diary.', 'Detailed instructions for transport, storage, preparation, and administration of IMP are provided to', 'the patient and parent(s)/caregiver(s)/legal guardian(s). Parent(s)/caregiver(s)/legal guardian(s)', 'will complete a dosing diary to document compliance with injection of IMP.', '8.2', 'NONINVESTIGATIONAL MEDICINAL PRODUCT(S)', '8.2.1 Inhaled Corticosteroids and Second Controller Medication', 'The recognized second controller medication for combined use with medium- or high-dose ICS', '(dose-levels in children 6 to <12 years old, as per Appendix A) as background therapy during this', 'study (only one controller is permitted; see eligibility criterion No. 14 in Section 7.2.2) will', 'include the following classes: LABA, LTRA, LAMA, or methylxanthines. Please refer to', 'Appendix B for an indicative (not exhaustive) list of recognized second controller medications', 'approved for this study. These second controller medications will not be dispensed or supplied by', 'the Sponsor.', 'Property of the Sanofi Group - strictly confidential', 'Page 50', 'VV-CLIN-0528583 6.0']\n\n###\n\n", "completion": "END"}